Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

OMF Welcomes Alain Moreau, PhD, to our Scientific Advisory Board

Dr. Alain Moreau joins the OMF Scientific Advisory Board

OMF is honored to welcome Canadian researcher, Dr. Alain Moreau, to our Scientific Advisory Board (SAB,) which is directed by Ronald W. Davis. PhD.

“I initially decided to invite Dr. Moreau to join our ME / CFS Working Group because he demonstrated that he could take multiple novel approaches to understanding the disease. For example, he has conducted an extensive analysis of the microRNAs that can exert major controls over cell function. It is clear that his work will be very complementary to the research of other investigators.  I was pleased to invite him to join the OMF Scientific Advisory Board. It extends our international collaboration for solving ME / CFS.”

Ron Davis, PhD

Recently, Dr. Moreau was appointed Director of the Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis Research Network, a national research network funded by the Canadian Institute of Health Research.

Additionally, a generous Canadian family made an anonymous, designated gift to OMF Canada of $1.2 million over two years to support Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) research undertaken in Dr. Moreau’s Montreal-based laboratory.

“The support of Open Medicine Foundation Canada arrives at a critical time for my team, and we wish to thank all of you who are contributing to our research efforts to decipher the ME / CFS enigma. I truly believe that we are at the brink of a breakthrough. Still, success will come only by working in a collaborative manner, not in silos, because together we can achieve the excellence necessary to end ME / CFS”.

Alain Moreau PhD

Welcome, Dr. Moreau, to OMF’s global collaboration team.

Learn more about Dr. Moreau

 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo